Work

Pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study

Year: 2016

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw373.76

Authors: R. de Wit, A.M. Kamat, J. Bellmunt, T.K. Choueiri, K. Nam, M. De Santis, R. Dreicer, N.M. Hahn, R. Perini, A.O. Siefker-Radtke, G. Sonpavde, J.A. Witjes, S. Keefe, D. Bajorin

Institutions: Erasmus MC Cancer Institute, The University of Texas MD Anderson Cancer Center, Harvard University, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Dana-Farber Brigham Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States), University of Warwick, University of Virginia Medical Center, University of Virginia, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of Alabama at Birmingham, Radboud University Nijmegen, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Merck, Novartis, Exelixis, Pfizer Pharmaceuticals

OpenAlex ID: W2588401808

FWCI: 0.332

Cites:

Cited by: 2

Related to: 10